Navigation Links
Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer
Date:4/4/2011

ORLANDO, Fla., April 4, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results today from two preclinical studies of molecules that target genetic mutations and disable specific signaling pathways that can lead to cancer.  The studies evaluated two unique molecules – a JAK2 inhibitor and a Hedgehog inhibitor – with results presented during the American Association for Cancer Research (AACR) 102nd Annual Meeting in Orlando, Fla.  

Signaling pathways within cells regulate genes that underlie crucial biological processes including cell division, embryonic development and immunity.  When these networks of proteins misfire, many types of cancer can result.  At AACR, data from Lilly showed how these pipeline molecules target out-of-control signaling pathways.

"Lilly is focused on developing therapies tailored for an individual patient's needs – such as a cancer treatment that targets a specific genetic mutation," said Jonathan M. Yingling, Ph.D., vice president of oncology research at Lilly.  "We believe beginning this evaluation early in the preclinical stage, as we have with these two studies, may lead to more focused, efficient clinical trials and, in turn, speed drug discovery."

LY2784544: JAK2 Inhibitor (Abstract # 2820)

Research presented at AACR's New Small Molecule Therapeutics mini-symposium suggested that the investigational compound LY2784544, a small-molecule JAK2 inhibitor, blocks a specific, difficult-to-isolate, signaling pathway that can lead to the development of cancer cells.  

Specifically, Lilly researchers chose to study inflammatory breast cancer (IBC) cells because these cells support their own survival by secreting chemicals known as growth factors, which allow them to break away from the primary tumor, multiply and then cluster together into tumor sp
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Norgine B.V. today announced ... volume bowel preparation, NER1006, presented at the 79 th ... Gastroenterology (ACG), Philadelphia, PA , has ... and co-primary endpoint of cleansing success. The study demonstrated ... ® in screening colonoscopy patients. [1] ...
(Date:10/19/2014)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the ... to office-based dental, animal health and medical practitioners, announced ... Inc., a leading full-service provider of dental consumables, implants ... into Japan , the world,s 2 ... the number of countries in which the Company operates. ...
(Date:10/17/2014)... , Oct. 17, 2014  Training market researchers ... critical success factor in today,s highly competitive global ... research organizations that effectively and efficiently produce high ... service area. Effective training programs ... earn recognition from internal clients by developing analysts ...
Breaking Medicine Technology:Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2
... , MALVERN, ... a privately held biopharmaceutical company, and Cephalon, Inc. (Nasdaq: ... trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic ... in the co-primary endpoints of changes in esophageal eosinophil levels ...
... , WAPPINGERS ... Medical, in alliance with the American Academy of Pediatrics (AAP), ... with Laerdal,s SimNewB (TM) neonatal patient simulator. SimNewB is designed ... to facilitate training for treatment of other critical medical conditions ...
Cached Medicine Technology:Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 2Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 3Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 4Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 5Neonatal Scenarios Developed in Partnership with the American Academy of Pediatrics (AAP), Utilize the NRP Curriculum to Advance Newborn Care 2Neonatal Scenarios Developed in Partnership with the American Academy of Pediatrics (AAP), Utilize the NRP Curriculum to Advance Newborn Care 3
(Date:10/20/2014)... 20, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Sit and Slim II . ... to purchase or use Sit and Slim II because it ... is promoted as weight loss product on various websites and ... market in 2010 for safety reasons, can significantly increase blood ...
(Date:10/20/2014)... October 20, 2014 Rockynol Retirement ... Center on Oct. 14. The $11 million project will ... and a cooked-to-order kitchen with full-service restaurant style dining. ... choice for first class Assisted Living apartments,” said Kara ... deserve the highest quality of care and this investment ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Based ... are the only imaging assays capable of determining ... single test.  With these three dimensions of high-resolution ... to detect the widest range of disease-causing genetic ... missed by other genomic tools, including today’s advanced ...
(Date:10/20/2014)... Final Cut Pro X Plugin developers from Pixel ... for FCPX filmmakers . , “Fun, cool, and simple ... theme” Says Christina Austin, CEO of Pixel Film Studios. “It ... Citrus comes with all the tools needed for a ... for added style, a title screen for an introduction, two ...
(Date:10/20/2014)... 2014 It’s hard to imagine what it’s ... vulnerable children around the world, it’s a reality. And while ... children are forced to walk barefoot on rocky terrain or ... play with their friends. , Buckner International's Shoes ... Radio in October to encourage support for Air1 and ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
... Paragon Medsystems unveiled their new corporate identity at ... Effective immediately, the company name will be California MedTech.The ... providing turnkey development and manufacturing services to the medical ... focus on the medtech sector, as well as our ...
... Hepatocellular carcinoma (HCC) is a highly aggressive form of ... cancers worldwide. Devanand Sarkar and colleagues, at Virginia Commonwealth ... gene that is expressed at high levels in human ... HCC progression. They therefore suggest that targeting this gene ...
... the two might be genetic, researchers say , , MONDAY, Feb. ... melanoma are twice as likely to develop Parkinson,s disease, a ... are not clear, other studies have shown that people with ... "For people with a family member with melanoma, they may ...
... patients who undergo surgery at teaching-intensive hospitals have ... these better survival rates apparently occur in white ... in surgical outcomes for patients in teaching-intensive hospitals ... from other studies," said study leader Jeffrey H. ...
... improved expertise after surgery, but reasons unclear, study finds ... are less likely to die of post-surgery complications at ... doesn,t apply to black patients, a U.S. study. finds. ... at The Children,s Hospital of Philadelphia and the University ...
... technological breakthroughsCLEVELAND, Feb. 16 NorTech, in partnership ... to announce the winners of its annual Innovation ... Northeast Ohio innovators who are impacting the lives ... world. This year, a distinguished panel of judges ...
Cached Medicine News:Health News:Paragon Medsystems Becomes California MedTech 2Health News:Family History of Melanoma Doubles Parkinson's Risk 2Health News:White Patients Benefit More Than Blacks in Surviving Surgical Complications at Teaching Hospitals 2Health News:White Patients Benefit More Than Blacks in Surviving Surgical Complications at Teaching Hospitals 3Health News:Teaching Hospitals' Post-Op Gains Not Extended to Blacks 2Health News:NorTech, Crain's Cleveland Business Honor 2009 Innovation Award Winners 2Health News:NorTech, Crain's Cleveland Business Honor 2009 Innovation Award Winners 3Health News:NorTech, Crain's Cleveland Business Honor 2009 Innovation Award Winners 4Health News:NorTech, Crain's Cleveland Business Honor 2009 Innovation Award Winners 5
... The compact Allegra X-22 Series is up to 10 ... a library of 11 rotors, the Allegra X-22 Series ... Features: Only 18 inches / 46 cm ... 22,065 x g 3 different ways to Spin ...
... Optimal for Subcellular Fractionation, ... x g (30,000 rpm) with ... from 0.25 up to 85 ... 2° C to 40° C ...
... to accommodate over 55 centrifuge tubes, bottles, ... labile samples. Incorporating the latest technology, these ... quick cooling from 22 C to 4 ... brushless motor, low pitch 62 dBA quiet ...
Inquire...
Medicine Products: